Truist Cuts Agios Pharmaceuticals Price Target to $35 From $37
Truist Securities cut its Agios Pharmaceuticals price target to $35 from $37 and kept a Buy rating, Dow Jones Newswires reports.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Dow Jones Newswires reports that Truist Securities lowered its price target on Agios Pharmaceuticals shares to $35 from $37. The analyst firm kept its rating at Buy. The ratings information is attributed to Benzinga.
why it matters
A single brokerage changing its price target is a routine event. It usually moves the stock less than company results or news about the company's drug pipeline.
tags
instruments
on polymarket
sources
- Agios Pharmaceuticals Price Target Cut to $35.00/Share From $37.00 by Truist Securities — Dow Jones Newswires, 6 November 2026 at 17:55 UTC
- Atlassian Price Target Cut to $200.00/Share From $250.00 by Truist Securities — Dow Jones Newswires, 6 November 2026 at 18:01 UTC
- Five9 Price Target Cut to $35.00/Share From $40.00 by Truist Securities — Dow Jones Newswires, 6 November 2026 at 18:14 UTC
- Cummins Price Target Cut to $637.00/Share From $779.00 by Truist Securities — Dow Jones Newswires, 6 November 2026 at 18:10 UTC
- James Hardie Industries Price Target Cut to $37.00/Share From $40.00 by Truist Securities — Dow Jones Newswires, 6 November 2026 at 18:22 UTC
- Magnolia Oil & Gas Price Target Raised to $37.00/Share From $35.00 by Truist Securities — Dow Jones Newswires, 6 November 2026 at 18:29 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗